查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1565660

口服抗病毒市場，按類型、給藥途徑、應用、最終用戶、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Oral Antiviral Market, By Type, By Route of Administration, By Application, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 316 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年口服抗病毒藥物市場規模為379.0432億美元，2024年至2032年複合年成長率為2.90%。

口服抗病毒藥物市場-市場動態

病毒性疾病盛行率的增加促進了口服抗病毒藥物市場的成長

病毒性疾病的日益流行極大地推動了口服抗病毒藥物市場的成長。據世界衛生組織 (WHO) 稱，流感和 COVID-19 仍然是全球主要的健康問題，每年有數百萬人受到影響。美國疾病管制與預防中心 (CDC) 報告稱，在 COVID-19 大流行期間，抗病毒處方數量激增，凸顯了口服抗病毒藥物在管理廣泛感染方面的關鍵作用。例如，Paxlovid 是一種治療 COVID-19 的口服抗病毒藥物，在上市第一年就為超過 50 萬名患者開了處方。此外，單純皰疹等慢性病毒性疾病的增加增加了對有效口服治療的需求。隨著全球對抗病毒性疾病的關注不斷加強，抗病毒藥物開發的進步和擴大這些藥物的使用範圍是推動市場成長的關鍵因素。

口服抗病毒藥物市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 2.90% 左右的複合年成長率成長

根據類型細分，預計核苷類似物將在 2023 年顯示最大的市場佔有率

根據給藥途徑細分，平板電腦是 2023 年的主導類型

根據應用細分，COVID-19 是 2023 年的主導類型

按地區分類，北美是 2023 年的主要收入來源

口服抗病毒藥物市場-細分分析：

全球口服抗病毒藥物市場根據類型、給藥途徑、應用、最終用戶和地區進行細分。

市場依類型分為四大類：核苷類似物、蛋白酶抑制劑、神經氨酸酶抑制劑和聚合酶抑制劑。核苷類似物因其對各種病毒感染的廣泛功效而引領市場。隨後是蛋白酶抑制劑，針對特定病毒提供針對性的作用。神經氨酸酶抑制劑對於流感治療很重要，而聚合酶抑制劑也很重要，但不太常用。

根據給藥途徑，市場分為三類：藥片、膠囊和口服混懸劑。片劑因其便利性和劑量準確性而成為最受歡迎的給藥途徑。膠囊緊隨其後，以不同的形式提供類似的好處。口服混懸液的使用頻率較低，但對於吞嚥藥片或膠囊有困難的患者很有價值。

口服抗病毒藥物市場 - 地理洞察

口服抗病毒藥物市場表現出明顯的地區差異，其中北美由於先進的醫療保健系統和高藥物採用率而處於領先地位。在美國，FDA 在 COVID-19 大流行期間迅速批准了 Paxlovid 等口服抗病毒藥物，導致其廣泛使用，第一年就服用了超過 1000 萬劑。歐洲緊隨其後，英國和德國等國家實施了全面的抗病毒治療計劃，顯著增加了市場需求。歐洲藥品管理局 (EMA) 透過快速批准新的抗病毒藥物來支持這一成長。在亞太地區，由於病毒感染率上升和醫療保健投資增加，日本和印度等國家正在經歷快速的市場擴張。例如，日本衛生部提倡使用口服抗病毒藥物來控制流感疫情。在醫療基礎設施不斷完善和抗病毒治療意識不斷提高的推動下，拉丁美洲、中東和非洲也是不斷成長的市場。

口服抗病毒藥物市場-競爭格局：

口服抗病毒藥物市場競爭激烈，主要參與者積極參與策略性措施以維持其市場地位。領先企業輝瑞 (Pfizer) 推出了針對 COVID-19 的 Paxlovid，並於 2022 年與比爾及梅琳達蓋茲基金會 (Bill & Melinda Gates Foundation) 合作，擴大低收入國家獲得抗病毒治療的機會。默克公司 (Merck & Co.) 憑藉用於治療 COVID-19 的 Molnupiravir 成為頭條新聞，並於 2021 年與 Ridgeback Biotherapeutics 合作，加速其開發和分銷。吉利德科學公司以 Veklury（瑞德西韋）而聞名，該公司不斷創新並擴大其抗病毒產品組合。此外，羅氏控股於2023年收購了抗病毒公司TIB Molbiol，以加強其在病毒診斷和治療領域的地位。這些公司正在利用合作夥伴關係、收購和合作來增強其抗病毒產品，並滿足全球對有效口服抗病毒療法日益成長的需求。

最新進展：

2021 年 11 月，輝瑞在研的 COVID-19 口服抗病毒藥物 PAXLOVID(TM) 在 2/3 期研究中證明，高風險成人的住院或死亡風險降低了 89%。該公司計劃很快向 FDA 提交資料以獲得緊急使用授權。

2021 年 10 月，默克和 Ridgeback Biotherapeutics 宣布，他們的研究性口服抗病毒藥物 molnupiravir 可將輕度至中度 COVID-19 患者的住院或死亡風險降低約 50%。他們計劃根據這些結果向 FDA 尋求緊急使用授權。

目錄

第1章：口服抗病毒藥物市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按類型分類的口服抗病毒藥物市場片段
    • 按給藥途徑分類的口服抗病毒藥物市場片段
    • 口服抗病毒藥物市場片段（依應用）
    • 最終用戶的口服抗病毒藥物市場片段
    • 按國家/地區分類的口服抗病毒藥物市場摘要
    • 按地區分類的口服抗病毒藥物市場片段
  • 競爭洞察

第 3 章：口服抗病毒藥物主要市場趨勢

  • 口服抗病毒藥物市場促進因素
    • 市場促進因素的影響分析
  • 口服抗病毒藥物市場限制
    • 市場限制影響分析
  • 口服抗病毒藥物市場機會
  • 口服抗病毒藥物市場未來趨勢

第 4 章：口服抗病毒藥物產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：口服抗病毒藥物市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：口服抗病毒藥物市場格局

  • 2023 年口服抗病毒藥物市佔率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：口服抗病毒藥物市場 - 按類型

  • 概述
    • 按類型分類的細分市場佔有率分析
    • 核苷類似物
    • 蛋白酶抑制劑
    • 神經氨酸酶抑制劑
    • 聚合酶抑制劑

第 8 章：口服抗病毒藥物市場 - 按給藥途徑

  • 概述
    • 按給藥途徑分類的細分市佔率分析
    • 平板電腦
    • 膠囊
    • 口服混懸劑

第 9 章：口服抗病毒藥物市場 - 按應用

  • 概述
    • 按應用分類的細分市場佔有率分析
    • 愛滋病
    • 肝炎
    • 流感
    • 新冠肺炎
    • 皰疹

第 10 章：口服抗病毒藥物市場 - 按最終用戶

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院
    • 診所
    • 家庭護理設置
    • 藥局

第 11 章：口服抗病毒藥物市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美口服抗病毒藥物主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按類型）
    • 北美市場規模與預測（按管理途徑）
    • 北美市場規模和預測（按應用）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲口服抗病毒藥物主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模與預測（按類型）
    • 歐洲市場規模與預測（按管理途徑）
    • 歐洲市場規模和預測（按應用）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區口服抗病毒藥物主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（按類型）
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模與預測（按應用）
    • 亞太地區市場規模和預測（按最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲口服抗病毒藥物主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按類型）
    • 拉丁美洲市場規模與預測（按管理途徑）
    • 拉丁美洲市場規模與預測（按應用）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲口服抗病毒藥物主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按類型）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模及預測（按應用）
    • 中東和非洲市場規模和預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 12 章：主要供應商分析 - 口服抗病毒藥物產業

  • 競爭儀表板
  • 公司簡介
    • AbbVie Inc.
    • Amgen Inc.
    • Aurobindo Pharma Limited
    • BioCryst Pharmaceuticals, Inc.
    • Bristol-Myers Squibb Company
    • Cipla Limited
    • Dr. Reddy's Laboratories Ltd.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Mylan NV (part of Viatris Inc.)
    • Novartis International AG
    • Pfizer Inc.
    • Roche Holding AG
    • Teva Pharmaceutical Industries Ltd.
    • Others

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV3856

REPORT HIGHLIGHT

Oral Antiviral Market size was valued at USD 37,904.32 Million in 2023, expanding at a CAGR of 2.90% from 2024 to 2032.

The Oral Antiviral Market focuses on medications taken by mouth to treat viral infections, providing an accessible and convenient option for patients. The market is experiencing growth due to the increasing prevalence of viral diseases such as influenza, COVID-19, and herpes simplex. For example, the global market saw a notable rise in oral antiviral treatments with the approval of Paxlovid in 2021, which has been widely utilized for COVID-19 management. However, challenges such as high drug costs and concerns about long-term resistance can impede market growth. Opportunities lie in the development of next-generation oral antivirals with broader efficacy and lower resistance profiles. Additionally, the rising emphasis on personalized medicine and the expansion of healthcare access in emerging markets are contributing to the growth of oral antiviral therapies. The growing number of antiviral drugs in the pipeline and increasing investment in research and development further underscore the market's potential.

Oral Antiviral Market- Market Dynamics

Increasing Prevalence of Viral Diseases Boosts Growth in Oral Antiviral Market

The increasing prevalence of viral diseases is significantly driving the growth of the Oral Antiviral Market. According to the World Health Organization (WHO), influenza and COVID-19 remain major global health concerns, with millions affected annually. The U.S. Centers for Disease Control and Prevention (CDC) reported a surge in antiviral prescriptions during the COVID-19 pandemic, highlighting the critical role of oral antivirals in managing widespread infections. For instance, Paxlovid, an oral antiviral for COVID-19, was prescribed to over 500,000 patients in its first year of availability. Additionally, the rise in chronic viral conditions, such as herpes simplex, has increased the demand for effective oral treatments. As the global focus on combating viral diseases intensifies, advancements in antiviral drug development and expanding access to these medications are crucial factors driving market growth.

Oral Antiviral Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 2.90% over the forecast period (2024-2032)

Based on Type segmentation, Nucleoside Analogues were predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Tablets was the leading type in 2023

Based on Application segmentation, COVID-19 was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Oral Antiviral Market- Segmentation Analysis:

The Global Oral Antiviral Market is segmented on the basis of Type, Route of Administration, Application, End-User, and Region.

The market is divided into four categories based on Type: Nucleoside Analogues, Protease Inhibitors, Neuraminidase Inhibitors, and Polymerase Inhibitors. Nucleoside analogues lead the market due to their broad efficacy against various viral infections. Protease inhibitors follow, offering targeted action against specific viruses. Neuraminidase inhibitors are significant for influenza treatment, while polymerase inhibitors are crucial but less commonly used.

The market is divided into three categories based on Route of Administration: Tablets, Capsules, and Oral Suspensions. Tablets are the most popular route of administration due to their convenience and dosage accuracy. Capsules follow closely, offering similar benefits with a different format. Oral suspensions are used less frequently but are valuable for patients who have difficulty swallowing tablets or capsules.

Oral Antiviral Market- Geographical Insights

The Oral Antiviral Market shows distinct regional variations, with North America leading due to advanced healthcare systems and high drug adoption rates. In the U.S., the FDA's rapid approval of oral antivirals like Paxlovid during the COVID-19 pandemic led to widespread use, with over 10 million doses administered in the first year. Europe follows closely, where countries such as the UK and Germany have implemented comprehensive antiviral treatment programs, significantly increasing market demand. The European Medicines Agency (EMA) has supported this growth by fast-tracking approvals for new antiviral drugs. In the Asia-Pacific region, countries like Japan and India are experiencing rapid market expansion due to rising viral infection rates and increased healthcare investments. For instance, Japan's Ministry of Health has promoted the use of oral antivirals in managing influenza outbreaks. Latin America and the Middle East & Africa are also growing markets, driven by increasing healthcare infrastructure and rising awareness of antiviral treatments.

Oral Antiviral Market- Competitive Landscape:

The Oral Antiviral Market is competitive, with major players actively engaging in strategic initiatives to maintain their market positions. Pfizer, a leading player, launched Paxlovid for COVID-19 and partnered with the Bill & Melinda Gates Foundation in 2022 to expand access to antiviral treatments in low-income countries. Merck & Co. has made headlines with its Molnupiravir for COVID-19, and in 2021, it collaborated with Ridgeback Biotherapeutics to accelerate its development and distribution. Gilead Sciences, known for Veklury (remdesivir), has continued to innovate and expand its antiviral portfolio. Additionally, Roche Holdings acquired the antiviral company TIB Molbiol in 2023 to strengthen its position in viral diagnostics and treatments. These companies are leveraging partnerships, acquisitions, and collaborations to enhance their antiviral offerings and address the growing global demand for effective oral antiviral therapies.

Recent Developments:

In November 2021, Pfizer's investigational COVID-19 oral antiviral, PAXLOVID(TM), demonstrated an 89% reduction in hospitalization or death risk in high-risk adults during a Phase 2/3 study. The company plans to submit data to the FDA for Emergency Use Authorization soon.

In October 2021, Merck and Ridgeback Biotherapeutics announced that their investigational oral antiviral, molnupiravir, reduced the risk of hospitalization or death by about 50% in mild to moderate COVID-19 patients. They plan to seek Emergency Use Authorization from the FDA based on these results.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ORAL ANTIVIRAL MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie Inc.
  • Amgen Inc.
  • Aurobindo Pharma Limited
  • BioCryst Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan N.V. (part of Viatris Inc.)
  • Novartis International AG
  • Pfizer Inc.
  • Roche Holding AG
  • Teva Pharmaceutical Industries Ltd.
  • Others

GLOBAL ORAL ANTIVIRAL MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Nucleoside Analogues
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Polymerase Inhibitors

GLOBAL ORAL ANTIVIRAL MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Tablets
  • Capsules
  • Oral Suspensions

GLOBAL ORAL ANTIVIRAL MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • HIV
  • Hepatitis
  • Influenza
  • COVID-19
  • Herpes

GLOBAL ORAL ANTIVIRAL MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Homecare Settings
  • Pharmacies

GLOBAL ORAL ANTIVIRAL MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Oral Antiviral Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Oral Antiviral Market Snippet by Type
    • 2.1.2. Oral Antiviral Market Snippet by Route of Administration
    • 2.1.3. Oral Antiviral Market Snippet by Application
    • 2.1.4. Oral Antiviral Market Snippet by End-User
    • 2.1.5. Oral Antiviral Market Snippet by Country
    • 2.1.6. Oral Antiviral Market Snippet by Region
  • 2.2. Competitive Insights

3. Oral Antiviral Key Market Trends

  • 3.1. Oral Antiviral Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Oral Antiviral Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Oral Antiviral Market Opportunities
  • 3.4. Oral Antiviral Market Future Trends

4. Oral Antiviral Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Oral Antiviral Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Oral Antiviral Market Landscape

  • 6.1. Oral Antiviral Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Oral Antiviral Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Nucleoside Analogues
    • 7.1.3. Protease Inhibitors
    • 7.1.4. Neuraminidase Inhibitors
    • 7.1.5. Polymerase Inhibitors

8. Oral Antiviral Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Tablets
    • 8.1.3. Capsules
    • 8.1.4. Oral Suspensions

9. Oral Antiviral Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 9.1.2. HIV
    • 9.1.3. Hepatitis
    • 9.1.4. Influenza
    • 9.1.5. COVID-19
    • 9.1.6. Herpes

10. Oral Antiviral Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Clinics
    • 10.1.4. Homecare Settings
    • 10.1.5. Pharmacies

11. Oral Antiviral Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Oral Antiviral Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Oral Antiviral Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Oral Antiviral Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Oral Antiviral Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Oral Antiviral Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Oral Antiviral Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. AbbVie Inc.
    • 12.2.2. Amgen Inc.
    • 12.2.3. Aurobindo Pharma Limited
    • 12.2.4. BioCryst Pharmaceuticals, Inc.
    • 12.2.5. Bristol-Myers Squibb Company
    • 12.2.6. Cipla Limited
    • 12.2.7. Dr. Reddy's Laboratories Ltd.
    • 12.2.8. Gilead Sciences, Inc.
    • 12.2.9. GlaxoSmithKline plc
    • 12.2.10. Johnson & Johnson Services, Inc.
    • 12.2.11. Merck & Co., Inc.
    • 12.2.12. Mylan N.V. (part of Viatris Inc.)
    • 12.2.13. Novartis International AG
    • 12.2.14. Pfizer Inc.
    • 12.2.15. Roche Holding AG
    • 12.2.16. Teva Pharmaceutical Industries Ltd.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us